DOCSLIB.ORG

TAG 2009 Pipeline Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TAG 2009 Pipeline Report maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bavitux- imab HCV-796 valopicitabine telaprevir TMC207 gatifloxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 triva- lent daprivirine SPL 7013 PRO 2000 DermaVir AGS-004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bavituximab HCV-796 valopicitabine telaprevir TMC207 gati- floxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalentHIV daprivirine TUBERCULO SPLSIS 7013 VI RALPRO HEPA 2000TITIS DermaV ir AGS- 004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bav- ituximab HCV-796 valopicitabine telaprevir TMC207 gatifloxacinD RUGOPC-67683S, DIAG NALOstiVACCS vCP1521, VACCIN EISSS, AP-001ND MRK Ad5 MICROBICIDES IN DEVELOPMENT trivalent daprivirine SPL 7013 PRO 2000 DermaVir AGS-004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bavituximab HCV-796 valopicitabine telaprevir TMC207 gati- floxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalent daprivirine SPL 7013 PRO 2000 DermaVir AGS- 004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirineTAG raltegravir 2009 VX-950 SCH 503034 taribavirin bav- ituximab HCV-796 valopicitabine telaprevir TMC207 gatifloxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalent daprivirine SPL 7013 PRO 2000 DermaVir AGS-004 maravirocPipeline TNX-355 apricitabineReport TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bavituximab HCV-796 valopicitabine telaprevir TMC207 gati- floxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalent daprivirine SPL 7013 PRO 2000 DermaVir AGS- 004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bav- ituximab HCV-796 valopicitabine telaprevir TMC207 gatifloxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalent daprivirine SPL 7013 PRO 2000 DermaVir AGS-004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bavituximab HCV-796 valopicitabine telaprevir TMC207 gati- maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine JULYraltegravir 2009 VX-950 SCH 503034 taribavirin bavitux- imab HCV-796 valopicitabine telaprevir TMC207 gatifloxacin OPC-67683TREATMENT AL VACTIONAC vCP1521 GROUP ISS P-001 MRK Ad5 triva- lent daprivirine SPL 7013 PRO 2000 DermaVir AGS-004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bavituximabLEI CHOU, HC V-MARK796 H ARRvalopicitabineINGTON, BOB HUtelaprevirFF, TMC207 gati- RICHARD JEFFERys, JAVID SYED, floxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalentAND CdaprivirineLAIRE WINGFI ELDSPL 7013 PRO 2000 DermaVir AGS- 004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bav- ituximab HCV-796 valopicitabine telaprevir TMC207 gatifloxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalent daprivirine SPL 7013 PRO 2000 DermaVir AGS-004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bavituximab HCV-796 valopicitabine telaprevir TMC207 gati- floxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalent daprivirine SPL 7013 PRO 2000 DermaVir AGS- 004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bav- ituximab HCV-796 valopicitabine telaprevir TMC207 gatifloxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalent daprivirine SPL 7013 PRO 2000 DermaVir AGS-004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bavituximab HCV-796 valopicitabine telaprevir TMC207 gati- floxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalent daprivirine SPL 7013 PRO 2000 DermaVir AGS- 004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bav- ituximab HCV-796 valopicitabine telaprevir TMC207 gatifloxacin OPC-67683 ALVAC vCP1521 ISS P-001 MRK Ad5 trivalent daprivirine SPL 7013 PRO 2000 DermaVir AGS-004 maraviroc TNX-355 apricitabine TMC-278 bevirimat etravirine raltegravir VX-950 SCH 503034 taribavirin bavituximab HCV-796 valopicitabine telaprevir TMC207 gati- HIV, TUBERCULOSIS, AND VIRAL HEPATITIS: DRUGS, DIAGNOSTICS, VACCINES, AND MICROBICIDES IN DEVELOPMENT TAG 2009 Pipeline Report JULY 2009 BY TREATMENT ACTION GROUP LEI CHOU, MARK HARRINGTON, BOB HUFF, RICHARD JEFFERYS, JAVID SYED, AND CLAIRE WINGFIELD ABOUT TAG The Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. You can reach TAG by phone at +1.212.253.7922. To find out more about TAG’s projects go to www.treatmentactiongroup.org. Treatment Action Group 611 Broadway, Suite 308 New York, NY 10012 Tel 212.253.7922 Fax 212.253.7923 [email protected] www.treatmentactiongroup.org ISBN 978-0-9819863-2-6 THIS REPORT IS DEDICATED TO Martin Delaney 1945–2009 Pioneering AIDS treatment activist Founder, Project Inform Table of Contents Introduction 1 Acknowledgments 3 Antiretroviral Drugs in Development 5 Hepatitis B Drug Development in 2009 15 Experimental Oral Agents Therapeutic Vaccines Tuberculosis Treatments 25 Latent TB Infection Active TB Disease Novel Compounds Tuberculosis Diagnostics 39 Health Post Level Peripheral Laboratory Level Reference Laboratory Level Tuberculosis Vaccines 59 Immune-Based Therapies and Preventive Technologies Pipeline 65 Prevention Vaccines Pre-Exposure Prophylaxis Microbicides Immune–Based Therapies Introduction BY MARK HARRINGTON This year’s Pipeline report shows, in brief, a lull in anti-HIV drug development, an alarming stasis in hepatitis B treatment research, renewed activity (after a gap of almost 40 years) in TB drug development, agonizing slow and incremental progress in TB diagnostics research, very preliminary human studies of several new TB vaccine candidates, a back-to-basics mood in the HIV vaccine research community, renewed hopes for efficacy in microbicide and pre-exposure prophylaxis, and no dramatic developments in the areas of immune-based therapies or therapeutic vaccines for HIV. In short, as Thomas Kuhn would have said, this report documents a period of relatively “normal” science, with its incremental steps forward and back, its halting progress, its occasional retreat from a blind alley. There is nothing as dramatic here as the bleak pessimism that enshrouded HIV vaccine research after the STEP study was prematurely terminated in 2007, nor the possibly overhyped HAART 2.0 breakthrough of that same year, when two new classes of anti-HIV drugs were introduced. Yet, as Richard Jefferys points out in the conclusion to his chapter herein, the despair of Berlin 1993 preceded the euphoria of the HAART revolution of Vancouver 1996 by just three years. We do not have a crystal ball; nor do we know whence the next breakthrough may come. Instead, in my view, the greatest challenges to AIDS research this year lie not in the discovery and development of a single new intervention but in the much harder questions of how best to use all the tools at our disposal to prevent and treat HIV. This was put extremely well by Kevin De Cock in his farewell address as the World Health Organization’s HIV director at the PEPFAR Implementers’ Meeting in Windhoek, Namibia, in June, 2009: Martin Luther King said that the arc of the moral universe is long but it bends towards justice. If public health is rooted in the science of epidemiology, its philosophic values are equity and social justice. We are entering perilous ethical and political waters, and current practice for poor people of color in the global South will not be judged well by history if it does not evolve with science and practice in the richer North. … The world cannot allow a permanently two tiered system of global AIDS treatment with late initiation of outmoded drugs reserved for the South. Nor can we hide behind lack of knowledge or the attitude of “let’s wait and see.” Equipoise no longer exists in the debate about early or late initiation, and today’s questions are “treat how early?” and “with what?” 1 TAG 2009 Pipeline Report It is unacceptable, in view of what is at stake—millions of lives, billions of dollars—that despite over three million people in the world on ART [antiretroviral therapy], we cannot definitively answer the question of when to start treatment. Allocation of Global Fund and PEPFAR resources must be based on evidence. There is ethical as well as medical need for a randomized controlled trial to determine optimal starting criteria in Africa, including assessment of the impact of immediate treatment on tuberculosis incidence. PEPFAR and the Global Fund could resolve these questions once and for all through applied research under field conditions, through a large simple trial, for example, with hard end points such as tuberculosis, AIDS, death. Some argue such a study is not needed because we will never have resources to treat more people earlier with better drugs. This is unpersuasive; rationing of health care is a universal reality but let rationing decisions be made transparently, with the involvement of all stakeholders, based on scientific understanding of cost and benefit. Despite challenges, political will and science could get us closer to one, or a few, global, once-
Load more

Recommended publications
  • Current Therapies for Chronic Hepatitis C
    Southern Illinois University Edwardsville SPARK Pharmacy Faculty Research, Scholarship, and Creative Activity School of Pharmacy 1-2011 Current Therapies for Chronic Hepatitis C McKenzie C. Ferguson Southern Illinois University Edwardsville, [email protected] Follow this and additional works at: https://spark.siue.edu/pharmacy_fac Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Ferguson, McKenzie C., "Current Therapies for Chronic Hepatitis C" (2011). Pharmacy Faculty Research, Scholarship, and Creative Activity. 4. https://spark.siue.edu/pharmacy_fac/4 This Article is brought to you for free and open access by the School of Pharmacy at SPARK. It has been accepted for inclusion in Pharmacy Faculty Research, Scholarship, and Creative Activity by an authorized administrator of SPARK. For more information, please contact [email protected],[email protected]. Chronic Hepatitis C & Current Therapies 1 Review of Chronic Hepatitis C & Current Therapies Reviews of Therapeutics Pharmacotherapy McKenzie C. Ferguson, Pharm.D., BCPS From the School of Pharmacy, Southern Illinois University Edwardsville, Department of Pharmacy Practice, Edwardsville, Illinois. Address for reprint requests : Southern Illinois University Edwardsville School of Pharmacy 220 University Park Drive, Ste 1037 Edwardsville, IL 62026-2000 Email: [email protected] Keywords : hepatitis C, HCV, ribavirin, interferon, peginterferon alfa-2a, peginterferon alfa-2b, albinterferon, taribavirin, telaprevir, therapeutic efficacy, safety The author received no sources of support in the form of grants, equipment, or drugs. Chronic Hepatitis C & Current Therapies 2 ABSTRACT Hepatitis C virus affects more than 180 million people worldwide and as many as 4 million people in the United States. Given that most patients are asymptomatic until late in disease progression, diagnostic screening and evaluation of patients that display high-risk behaviors associated with acquisition of hepatitis C should be performed.
    [Show full text]
  • Download Article PDF/Slides
    Kan Lu, PharmD New Antiretrovirals for Based on a presentation at prn by Roy M. Gulick, md, mph the Treatment of HIV: Kan Lu, PharmD | Drug Development Fellow University of North Carolina School of Pharmacy Chapel Hill, North Carolina The View in 2006 Roy M. Gulick, md, mph Reprinted from The prn Notebook® | october 2006 | Dr. James F. Braun, Editor-in-Chief Director, Cornell Clinical Trials Unit | Associate Professor of Medicine, Meri D. Pozo, PhD, Managing Editor. Published in New York City by the Physicians’ Research Network, Inc.® Weill Medical College of Cornell University | New York, New York John Graham Brown, Executive Director. For further information and other articles available online, visit http://www.prn.org | All rights reserved. ©october 2006 substantial progress continues to be made in the arena of cokinetics and a long extracellular half-life of approximately 10 hours antiretroviral drug development. prn is again proud to present its annual (Zhu, 2003). During apricitabine’s development, a serious drug interac- review of the experimental agents to watch for in the coming months and tion with lamivudine (Epivir) was noted. Although the plasma years. This year’s review is based on a lecture by Dr. Roy M. Gulick, a long- concentrations of apricitabine were unaffected by coadministration of time friend of prn, and no stranger to the antiretroviral development lamivudine, the intracellular concentrations of apricitabine were reduced pipeline. by approximately sixfold. Additionally, the 50% inhibitory concentration To date, twenty-two antiretrovirals have been approved by the Food (ic50) of apricitabine against hiv with the M184V mutation was increased and Drug Administration (fda) for the treatment of hiv infection.
    [Show full text]
  • Ep 2531027 B1
    (19) TZZ ¥_Z _T (11) EP 2 531 027 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4985 (2006.01) A61K 31/52 (2006.01) 06.05.2015 Bulletin 2015/19 A61K 31/536 (2006.01) A61K 31/513 (2006.01) A61K 38/55 (2006.01) A61P 31/18 (2006.01) (21) Application number: 11737484.3 (86) International application number: (22) Date of filing: 24.01.2011 PCT/US2011/022219 (87) International publication number: WO 2011/094150 (04.08.2011 Gazette 2011/31) (54) Therapeutic combination comprising dolutegravir, abacavir and lamivudine Therapeutische Zusammensetzung enthaltend Dolutegravir, Abacavir und Lamivudine Combinaison thérapeutique comprenant du dolutégravir, de l’abacavir et de la lamivudine (84) Designated Contracting States: (74) Representative: Gladwin, Amanda Rachel AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GlaxoSmithKline GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Global Patents (CN925.1) PL PT RO RS SE SI SK SM TR 980 Great West Road Designated Extension States: Brentford, Middlesex TW8 9GS (GB) BA ME (56) References cited: (30) Priority: 27.01.2010 US 298589 P WO-A1-2010/011812 WO-A2-2009/148600 US-A1- 2006 084 627 US-A1- 2006 084 627 (43) Date of publication of application: US-A1- 2008 076 738 US-A1- 2009 318 421 12.12.2012 Bulletin 2012/50 US-A1- 2009 318 421 US-B1- 6 544 961 (73) Proprietor: VIIV Healthcare Company • SONG1 et al: "The Effect of Ritonavir-Boosted Research Triangle Park, NC 27709 (US) ProteaseInhibitors on the HIV Integrase Inhibitor, S/GSK1349572,in Healthy Subjects", INTERNET , (72) Inventor: UNDERWOOD, Mark, Richard 15 September 2009 (2009-09-15), XP002697436, Research Triangle Park Retrieved from the Internet: URL:http: North Carolina 27709 (US) //www.natap.org/2009/ICCAC/ICCAC_ 52.htm [retrieved on 2013-05-21] Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Trends in Antiretroviral Treatment in Australia
    AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD) ANNUAL REPORT (Volume 20, Number 1: December 2020) 2020 Clinical characteristics of overseas-born men who have sex with men (MSM) in the AHOD cohort and implications for clinical practice In Australia HIV notifications are increasing among overseas-born men who have sex with men (MSM), particularly among Asian-born MSM. Australian evidence suggests that culturally and/or linguistically diverse populations are less likely to start treatment early irrespective of CD4 cell count at diagnosis, but little is known about response once in care. Using data from AHOD, Jolie L Hutchinson and colleagues (2020) compared treatment response in overseas-born MSM from non-English-speaking countries with Australian-born MSM, further categorised based on participation in the Australian Temporary Residents Access Study (ATRAS) which provide temporary residents ineligible for Medicare, access to HIV treatment. ATRAS patients were chosen as the closest surrogate to identifying newly arrived overseas-born MSM. The authors explored the time to first virological suppression (VS) (viral load (VL) <400 copies/mL) and time to virological failure (VF) (>400 copies/mL after suppression). CD4 cell counts and VL measurements were taken at treatment initiation. Adjusted Hazard Ratios (HR) are reported with 95% CI. Results, as shown in figure 1, indicate that overseas-born MSM did not differ significantly in the rate of VS or in the rate of first VF after suppression. This result is different from findings in other settings, and differences may, in part, be explained by the nature of healthcare provision. In Australia, all residents can access ART for free or with a small co-payment; those ineligible for Medicare can get pharmaceutical company-provided ART which is not necessarily straightforward for non-English speakers.
    [Show full text]
  • Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for Biomedical Research, Inc
    VIROLOGICA SINICA, August 2010, 25 (4):246-266 DOI 10.1007/s12250-010-3140-2 © Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2010 Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for BioMedical Research, Inc. Cambridge, Massachusetts 02139, USA) Abstract: Over 170 million people worldwide are infected with hepatitis C virus (HCV), a major cause of liver diseases. Current interferon-based therapy is of limited efficacy and has significant side effects and more effective and better tolerated therapies are urgently needed. HCV is a positive, single-stranded RNA virus with a 9.6 kb genome that encodes ten viral proteins. Among them, the NS3 protease and the NS5B polymerase are essential for viral replication and have been the main focus of drug discovery efforts. Aided by structure-based drug design, potent and specific inhibitors of NS3 and NS5B have been identified, some of which are in late stage clinical trials and may significantly improve current HCV treatment. Inhibitors of other viral targets such as NS5A are also being pursued. However, HCV is an RNA virus characterized by high replication and mutation rates and consequently, resistance emerges quickly in patients treated with specific antivirals as monotherapy. A complementary approach is to target host factors such as cyclophilins that are also essential for viral replication and may present a higher genetic barrier to resistance. Combinations of these inhibitors of different mechanism are likely to become the essential components of future HCV therapies in order to maximize antiviral efficacy and prevent the emergence of resistance.
    [Show full text]
  • Reviews in Basic and Clinical Gastroenterology
    GASTROENTEROLOGY 2010;138:447–462 REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY REVIEWS IN BASIC AND CLINICAL John P. Lynch and David C. Metz, Section Editors GASTROENTEROLOGY Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection CHRISTOPH SARRAZIN and STEFAN ZEUZEM J. W. Goethe-University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany Chronic hepatitis C virus (HCV) infection is one of agents that are also named specific, targeted antiviral the major causes of cirrhosis, hepatocellular carci- therapies (STAT-C) for HCV infection are in phase 1–3 noma, and liver failure that leads to transplantation. trials. We review resistance to DAA agents, focusing on The current standard treatment, a combination of compounds in development such as reagents that target pegylated interferon alfa and ribavirin, eradicates the the HCV nonstructural (NS)3 protease, the NS5A pro- virus in only about 50% of patients. Directly acting tein, and the RNA-dependent RNA polymerase NS5B. We antiviral (DAA) agents, which inhibit HCV replica- also discuss indirect inhibitors or compounds that in- tion, are in phase 1, 2, and 3 trials; these include hibit HCV replication by not yet completely resolved reagents that target the nonstructural (NS)3 protease, mechanisms, such as cyclophilin inhibitors, nitazox- the NS5A protein, the RNA-dependent RNA-polymer- anide, and silibinin (Table 1, Figure 1). ase NS5B, as well as compounds that directly inhibit HCV replication through interaction with host cell Parameters That Affect Resistance proteins. Because of the high genetic heterogeneity of Heterogeneity of HCV HCV and its rapid replication, monotherapy with HCV has a high rate of turnover; its half-life was DAA agents poses a high risk for selection of resistant estimated to be only 2–5 hours, with the production and variants.
    [Show full text]
  • Taribavirin.Pdf
    Virologic Response Rates of Weight-Based Taribavirin Versus Ribavirin in Treatment-Naive Patients with Genotype 1 Chronic Hepatitis C Fred Poordad,1 Eric Lawitz,2 Mitchell L. Shiffman,3 Tarek Hassanein,4 Andrew J. Muir,5 Bruce R. Bacon,6 Jamie Heise,7 Deanine Halliman,7 Eric Chun,7 and Janet Hammond7 Ribavirin-induced hemolytic anemia can prompt dose reductions and lower sustained virologic response (SVR) rates in the treatment of patients with chronic hepatitis C. The study aimed to determine if weight-based dosing of taribavirin (TBV), an oral prodrug of ribavirin (RBV), demonstrated efficacy comparable to RBV while maintaining its previ- ously demonstrated anemia advantage with fixed dose administration. A U.S. phase 2b randomized, open-label, active-controlled, parallel-group study was conducted in 278 treatment-naive patients infected with genotype 1 who were stratified by body weight and baseline viral load. Patients were randomized 1:1:1:1 to receive TBV (20, 25, or 30 mg/kg/ day) or RBV (800-1400 mg/day) with pegylated interferon alfa-2b for 48 weeks. The SVR rates in this difficult-to-cure patient demographics (mean age, 49 years; 61% male; 30% African American or Latino; high viral load; advanced fibrosis; and mean weight, 82 kg) were 28.4%, 24.3%, 20.6%, and 21.4% in the 20, 25, and 30 mg/kg TBV groups and the RBV group, respectively. There were no statistical differences in the efficacy analyses. Ane- mia rates were significantly lower (P < 0.05) in the 20 and 25 mg/kg/day TBV treatment groups (13.4% and 15.7%, respectively) compared to RBV (32.9%).
    [Show full text]
  • Synthesis and Development of Long-Acting Abacavir Prodrug Nanoformulations
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Summer 8-19-2016 Synthesis and Development of Long-Acting Abacavir Prodrug Nanoformulations Dhirender Singh University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Pharmaceutical Preparations Commons, and the Virus Diseases Commons Recommended Citation Singh, Dhirender, "Synthesis and Development of Long-Acting Abacavir Prodrug Nanoformulations" (2016). Theses & Dissertations. 140. https://digitalcommons.unmc.edu/etd/140 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. SYNTHESIS AND DEVELOPMENT OF LONG-ACTING ABACAVIR PRODRUG NANOFORMULATIONS by Dhirender Singh A DISSERTATION Presented to the Faculty of the Graduate School in the University of Nebraska Medical Center in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Department of Pharmaceutical Science Under the Supervision of Dr. Howard E. Gendelman University of Nebraska Medical Center, Omaha, Nebraska August 2016 Supervisory Committee: Howard E. Gendelman, M.D. Ram Mahato, Ph.D JoEllyn M. McMillan, Ph.D. David Oupicky, Ph.D SYNTHESIS AND DEVELOPMENT OF LONG-ACTING ABACAVIR PRODRUG NANOFORMULATIONS Dhirender Singh, Ph.D. University of Nebraska Medical Center, 2016 Supervisor: Howard E Gendelman, M.D. Over the past decade, work from our laboratory has demonstrated the potential of targeted nanoformulated antiretroviral therapy (nanoART) to produce sustained high plasma and tissue drug concentrations for weeks following a single intramuscular (IM) administration that can suppress ongoing viral replication and mitigate dose associated viral resistance.
    [Show full text]
  • 14-258 Phrma HIV/AIDS2014 0819.Indd
    2014 MEDICINES IN DEVELOPMENT REPORT HIV/AIDS PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Company Researchers Are Developing More Than 40 Medicines and Vaccines For HIV Infection Treatment and Prevention Medicines and Vaccines in Globally, approximately 35 million people effective therapies, and preventative Development for HIV Infection are infected with human immunodefi - vaccines. These medicines and vaccines ciency virus (HIV), the virus that causes are either in clinical trials or awaiting Application acquired immune defi ciency syndrome review by the U.S. Food and Drug Submitted (AIDS). However, new infections have Administration (FDA). Phase III dropped by 38 percent since 2001, Phase II The 44 medicines and vaccines in the according to UNAIDS, the Joint United Phase I development pipeline include: Nations Programme on HIV/AIDS. • A fi rst-in-class medicine intended to In the United States, more than 25 prevent HIV from breaking through 1.1 million people are living with HIV the cell membrane. and 15.8 percent of those are unaware they are infected, according to the • A cell therapy that modifi es a U.S. Centers for Disease Control and patient’s own cells in an attempt to Prevention (CDC). Although the U.S. make them resistant to HIV. HIV/AIDS-related death rate has fallen 16 by more than 80 percent since the introduction of antiretroviral therapies in Contents 1995, new HIV infections have stabilized HIV Medicines and Vaccines in at approximately 50,000 each year, Development ......................................2 according to the CDC. Incremental Innovation in HIV/AIDS Treatment .......................... 4 Since AIDS was fi rst reported in 1981, Access to HIV/AIDS Medicines in nearly 40 medicines have been approved Exchange Plans ...................................5 to treat HIV infection in the United Facts About HIV/AIDS ........................7 States.
    [Show full text]
  • Polymerase Inhibitors
    New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14th - 15th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2 p7 NS2 NS3 NS4A NS4B NS5A NS5B NS5A NS3 Bifunctional NS5B RNA-dependent protease / helicase RNA polymerase Antiviral Activity of DAAs Vary Among and Within Classes 3-14 day monotherapy in genotype 1 patients NS3 protease inhibitors NS5A inhibitors non-nucleoside inhibitors nucleos/tide inhibitors Median or Mean HCV RNA Decline (log IU/mL) Median or Mean HCV RNA BCP, boceprevir; TVP, telaprevir. Sarrazin C, Zeuzem S. Gastroenterology. 2010;138:447-62. Characteristics of DAAs and HTAs Efficacy Genotype Barrier to independency resistance NS3/4A (protease inhibitors) +++ ++ + - ++ NS5A +++ + - ++ + - ++ NS5B (nucleosides) + - +++ +++ +++ NS5B (non-nucleosides) + - ++ + + Cyclophilin Inhibitors ++ +++ +++ Nucleosidic polymerase inhibitors • RG-7128 (Mericitabine): moderate efficacy, safe • GS-7977 (Sofosbuvir): high efficacy, safe • Alios-2200 = VX135: high efficacy, early phase 2 • NM-283 (Valopicitabine): low efficacy, GI toxicity > • R-1626: moderate efficacy, lymphopenia > • INX-189 = BMS-986094: high efficacy, cardiac tox. > • IDX-184: moderate efficacy, on hold • PSI-938: high efficacy, hepatotoxicity > Nucleosidic polymerase inhibitors • RG-7128 (Mericitabine): moderate efficacy, safe • GS-7977 (Sofosbuvir): high efficacy, safe • Alios-2200 = VX135: high efficacy, early phase 2 • NM-283 (Valopicitabine): low efficacy, GI toxicity > • R-1626: moderate efficacy, lymphopenia > • INX-189 = BMS-986094: high efficacy, cardiac tox. > • IDX-184: moderate efficacy, on hold • PSI-938: high efficacy, hepatotoxicity > PROPEL study: Efficacy and safety of MCB + PR in G1/4 treatment-naive patients . Mericitabine nucleoside analog MCB 500 mg 12 wk (RVR-guided) polymerase inhibitor 100 MCB 1000 mg 8 wk (RVR-guided) MCB 1000 mg 12 wk (RVR-guided) .
    [Show full text]
  • Current Status and Prospects of HIV Treatment
    Available online at www.sciencedirect.com ScienceDirect Current status and prospects of HIV treatment 1 2 Tomas Cihlar and Marshall Fordyce Current antiviral treatments can reduce HIV-associated at suppressing plasma viremia, and significant progress morbidity, prolong survival, and prevent HIV transmission. has been made toward regimen simplification through the Combination antiretroviral therapy (cART) containing preferably combination of three active drugs into single-tablet regi- three active drugs from two or more classes is required for mens (STRs) (Figure 1) and optimization of drug profiles durable virologic suppression. Regimen selection is based on that maximize long-term tolerability and safety. Lifelong, virologic efficacy, potential for adverse effects, pill burden and chronic therapy without treatment interruption is the dosing frequency, drug–drug interaction potential, resistance standard of care, and the availability of multiple effective test results, comorbid conditions, social status, and cost. With drugs in several classes with differing resistance, safety, prolonged virologic suppression, improved clinical outcomes, and tolerability profiles provides choices after failure of and longer survival, patients will be exposed to antiretroviral first-line treatment. agents for decades. Therefore, maximizing the safety and tolerability of cART is a high priority. Emergence of resistance Herein, we review the current status of antiretroviral and/or lack of tolerability in individual patients require therapy and guidelines for HIV-infected adults, as well availability of a range of treatment options. Development of new as prospects for further innovation in HIV treatment to drugs is focused on improving safety (e.g. tenofovir benefit patients and optimize their long-term health. alafenamide) and/or resistance profile (e.g.
    [Show full text]
  • Wibke E. Diederich Holger Steuber Editors Therapy of Viral Infections 15 Topics in Medicinal Chemistry
    Topics in Medicinal Chemistry 15 Wibke E. Diederich Holger Steuber Editors Therapy of Viral Infections 15 Topics in Medicinal Chemistry Editorial Board: P. R. Bernstein, Rose Valley, USA A. Buschauer, Regensburg, Germany G. I. Georg, Minneapolis, USA J. A. Lowe, Stonington, USA U. Stilz, Malov, Denmark Prof. Dr. C. T. Supuran, Sesto Fiorentino (Firenze), Italy A. K. Saxena, Lucknow, India Aims and Scope Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the new topic-related series Topics in Medicinal Chemistry will cover all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimina- tion, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors. In references Topics in Medicinal Chemistry is abbreviated Top Med Chem and is cited as a journal. More information about this series at http://www.springer.com/series/7355 Wibke E. Diederich • Holger Steuber Editors Therapy of Viral Infections With contributions by E. Bo¨ttcher-Friebertsha¨user Á U. Chiacchio Á F. Christ Á E. Crespan Á J. Demeulemeester Á Z. Debyser Á U. Dietrich Á W.E. Diederich Á R. Du¨rr Á F.G.R. Ehlert Á C. Frezza Á A. Garbelli Á W. Garten Á S.V. Giofre` Á K. Hardes Á M.
    [Show full text]